Anika Therapeutics Inc (ANIK)

Anika Therapeutics, Inc. is a healthcare company focused on early intervention orthopedics and joint preservation. The company develops and markets products for osteoarthritis pain management, including Monovisc and Orthovisc, which are hyaluronic acid viscosupplement products, as well as Cingal, a single-injection non-opioid option for OA-related pain relief. Its portfolio also includes regenerative solutions such as Hyalofast, a resorbable scaffold for cartilage regeneration, and Tactoset, an injectable bone substitute designed for insufficiency fractures and hardware fixation support. In addition, Anika provides Integrity, Hyvisc for veterinary joint dysfunction in horses, Hyalobarrier for post-surgical adhesion prevention, ophthalmic products, and other high molecular weight HA products including Anikavisc and Nuvisc. Founded in 1983, the company is headquartered in Bedford, Massachusetts, and operates in the United States, Europe, and other international markets.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.